- Trade Name: Halaven (Eisai)
- Indications: Metastatic breast cancer in patients who have previously received at least two chemotherapeutic regimens (prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting); unresectable or metastatic liposarcoma in patients who have received a prior anthracycline-containing regimen
- Class: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Microtubule inhibitor
- Half-life: 40 hours
- FDA Approval Date: 11/15/2010
- Clinically important, potentially hazardous interactions with:
None known - Pregnancy: No available data but caused embryo-fetal toxicity in animal studies
- See adverse reactions attributed to class:
Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of eribulin in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 05/29/2026
